Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Mackie Research/Andre Uddin Loves Smacking The CEO Around!

<< Previous

Bullboard Posts

Next >>

Post by BlaineBorgon Jul 31, 2021 6:06am

492 Views

Post# 33636732

Mackie Research/Andre Uddin Loves Smacking The CEO Around!

Christopher Moreau, CEO @ Algernon stated early and often - Bellus Health is a "Pure Comparative" for Chronic Cough valuation. Does anyone believe anything the CEO says? Surely, Andre Uddin doesn't think so based on his latest so-called "upgrades" of both Algernon and Bellus Health:

May 2021 - Clinical stage drug developer Algernon Pharmaceuticals (Algernon Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials CSE:AGN) just received a rating upgrade from Research Capital analyst Andr Uddin, who in a report to clients on Monday moved from “Hold” to “Speculative Buy” while maintaining his $0.25 per share target.

Algernon upgraded at Research Capital - Cantech Letter

July 2021 - Research Capital Corporation analyst Andr Uddin has revised his view on Bellus Health (Bellus Stock Quote, Chart, News, Analysts, Financials TSX:BLU), changing his rating from “Hold” to “Speculative Buy” while raising his target price from $3.50/share (CDN) to $6.00/share, representing a projected return of 71 per cent.

Algernon upgraded at Research Capital - Cantech Letter

The CEO of Algernon Pharmaceuticals has tremendously hurt the company with his lack of leadership capabilities. Instead of pandering to the whims of Kulwant Malhi (Notorious Penny Flipper Of Algernon stock) he should have kept his eye on the ball for the Chronic Cough study. Furthermore, his decision to pigeonhole a tiny 20 person study halfway around the world in a tiny market was a colossal mistake from the outset. Yet, the CEO claims in black and white he's satisfied with the enrollment rate of the Chronic Cough study. The market obviously thinks otherwise. The CEO at Algernon has been a failure and his inability to see it for what it is does not bode well for the future of the company. Lots of luck needed from here on out because the CEO seems hell bent on keeping Algernon rolling around in the gutter of penny world. Surely, that makes the Board of Directors (they're all tied up in multiple pennyland junk companies tied to Kulwant Malhi) very happy. Christopher Moreau ("CEO") Loves The Status Quo.

What A True Clown Show @ Algernon Pharmceuticals Inc.